Controlled induction of human pancreatic progenitors produces functional beta-like cells \textit{in vitro}

Holger A Russ\textsuperscript{1}, Audrey V Parent\textsuperscript{1}, Jennifer J Ringler\textsuperscript{1}, Thomas G Hennings\textsuperscript{1}, Gopika G Nair\textsuperscript{1}, Mayya Shveygert\textsuperscript{2}, Tingxia Guo\textsuperscript{1,\dagger}, Sapna Puri\textsuperscript{1}, Leena Haataja\textsuperscript{3}, Vincenzo Cirulli\textsuperscript{4}, Robert Blelloch\textsuperscript{2}, Greg L Szot\textsuperscript{1}, Peter Arvan\textsuperscript{3} & Matthias Hebrok\textsuperscript{1,\ast}

Abstract

Directed differentiation of human pluripotent stem cells into functional insulin-producing beta-like cells holds great promise for cell replacement therapy for patients suffering from diabetes. This approach also offers the unique opportunity to study otherwise inaccessible aspects of human beta cell development and function \textit{in vitro}. Here, we show that current pancreatic progenitor differentiation protocols promote precocious endocrine commitment, ultimately resulting in the generation of non-functional polyhormonal cells. Omission of commonly used BMP inhibitors during pancreatic specification prevents precocious endocrine formation while treatment with retinoic acid followed by combined EGF/KGF efficiently generates both PDX6\textsuperscript{+} and subsequent PDX6\textsuperscript{+}/NKX6.1\textsuperscript{+} pancreatic progenitor populations, respectively. Precise temporal activation of endocrine differentiation in PDX6\textsuperscript{+}/NKX6.1\textsuperscript{+} progenitors produces glucose-responsive beta-like cells \textit{in vitro} that exhibit key features of \textit{bona fide} human beta cells, remain functional after short-term transplantation, and reduce blood glucose levels in diabetic mice. Thus, our simplified and scalable system accurately recapitulates key steps of human pancreas development and provides a fast and reproducible supply of functional human beta-like cells.

Keywords beta-like cells; diabetes; human embryonic stem cells; insulin-producing cells, pancreas

Subject Categories Methods & Resources; Molecular Biology of Disease; Stem Cells

DOI 10.15252/embj.201591058 | Received 22 January 2015 | Revised 26 March 2015 | Accepted 3 April 2015 | Published online 23 April 2015


See also: FM Spagnoli (July 2015)

Introduction

Diabetes mellitus type 1 and 2 (T1D, T2D) are diseases characterized by autoimmune destruction or progressive dysfunction and subsequent loss of insulin-producing pancreatic beta cells, respectively. Current treatments for both types of patients with diabetes consist of regulating blood glucose levels through injections of exogenous insulin. While this approach provides reasonable management of the diseases, unwanted risks and long-term complications persist due to the inability of tightly maintaining glucose levels within a normal physiological range. Complications include life-threatening episodes of hypoglycemia, as well as long-term complications from hyperglycemia resulting in micro- and macro-angiopathy leading to cardiovascular pathologies and kidney failure, as well as neuropathy. Thus, there is a need for distinct treatments that provide superior control of glucose metabolism to minimize or ideally eliminate long-term complications.

One existing approach to treating diabetes is transplantation of human cadaveric islet preparations into patients. This procedure typically results in better glycemic control, can render patients insulin independent for prolonged periods of time, and improves overall quality of life (Shapiro \textit{et al}, 2000; Posselt \textit{et al}, 2010; Barton \textit{et al}, 2012). However, the severe shortage of cadaveric organ donors, requirement for lifelong immunosuppression, and variability between islet preparations hampers the use of islet transplantation as a readily available treatment for people with diabetes. Consequently, numerous research efforts have focused on identifying abundant alternative sources of surrogate glucose-responsive insulin-producing cells (Zhou & Melton, 2008; Tudurí & Kieffer, 2011; Efrat & Russ, 2012; Hebrok, 2012; Nostro & Keller, 2012; Bouwens \textit{et al}, 2013; Pagliuca & Melton, 2013). One of the most appealing approaches is the directed differentiation into insulin-producing cells from pluripotent human embryonic stem cells (hESCs).
(D’Amour et al., 2005; Chen et al., 2009; Mfopou et al., 2010; Nostro et al., 2011; Van Hooij et al., 2011; Xu et al., 2011; Guo et al., 2013b; Shim et al., 2014) and, more recently, induced pluripotent stem cells (Maeh et al., 2009; Hua et al., 2013; Shang et al., 2014).

Comprehensive knowledge of signaling events and temporal transcription factor (TF) expression patterns during rodent pancreas organogenesis (Hebrok, 2003; Murtough & Melton, 2003; Pan & Wright, 2011; Seymour & Sander, 2011) have accelerated the identification of culture conditions that allow the generation of pancreatic cell types from human pluripotent stem cells (hPSCs). Early developmental stages, including definitive endoderm, gut tube-like cells, and pancreatic progenitors can be efficiently induced in vitro. However, subsequent transitions toward hormone-expressing cells in vitro are less efficient and frequently lead to the formation of a mixed population of different pancreatic progenitors and polyhormonal endocrine cells (D’Amour et al., 2006; Nostro et al., 2011; Guo et al., 2013a). Such polyhormonal cells express insulin among other hormones, but lack expression of key beta cell transcription factors and do not secrete insulin in vitro in response to a glucose challenge—the hallmark function of bona fide beta cells (D’Amour et al., 2006; Nostro et al., 2011; Guo et al., 2013a). Nonetheless, transplantation of such heterogeneous cultures into surrogate mice results in the formation of glucose-responsive beta-like cells after several months in vivo (Kroon et al., 2008; Rezania et al., 2012; Szot et al., 2015). Sophisticated sorting experiments identified progenitor cells expressing pancreatic and duodenal homeobox 1 TF (PDX1, also known as IPF1) and homeobox protein NKX6.1 as the source for these functional beta-like cells (Kelly et al., 2011). While polyhormonal cells have been identified in human fetal pancreas, suggesting that they may reflect aspects of the normal embryonic differentiation process (De Krijger et al., 1992; Riedel et al., 2011), increasing evidence indicates that hESC-derived polyhormonal cells preferentially give rise to single-hormone-positive alpha-like cells (Rezania et al., 2011). Thus, to fully replicate human beta cell development in vitro, it is imperative to better understand and accurately recapitulate the sequence of embryonic signals required for the proper specification of beta cell precursors, rather than alpha cell precursors.

During normal in vivo pancreatic organogenesis, functional beta cells are generated through a stepwise specification process starting with pancreatic progenitors, identified by the expression of Pdx1 (Herrera et al., 2002). While Pdx1+ cells can give rise to all pancreatic lineages (Herrera et al., 2002), the subsequent induction of Nkx6.1 in these cells restricts their differentiation potential to only endocrine and ductal cells (Schaffer et al., 2010). Endocrine differentiation is then initiated in Pdx1+/Nkx6.1+ progenitors by short-lived expression of the basic helix loop helix TF neurogenin 3 (Neurog3, also known as Ngn3) (Gu et al., 2002). Interestingly, the timing of Neurog3 expression has been shown to be crucial in promoting the formation of diverse endocrine islet cell types (Johansson et al., 2007). For example, precocious induction of endocrine differentiation by forced expression of Neurog3 in mice results predominantly in the generation of alpha cells (Johansson et al., 2007). Given that hESC-derived polyhormonal cells have been shown to give rise to alpha cells (Rezania et al., 2011), we hypothesized that the in vitro generation of polyhormonal endocrine cells results from premature assignment to the endocrine fate.

To address this issue, we performed a detailed stepwise analysis of pancreatic progenitor generation and endocrine induction. Most current protocols efficiently establish PDX1+ progenitors by using retinoic acid in combination with molecules to inhibit bone morphogenetic protein (BMP) and sonic hedgehog (SHH) signaling pathways, while simultaneously adding either fibroblast growth factor 10 or keratinocyte growth factor (KGF, also known as FGF7) (Mfopou et al., 2010; Nostro & Keller, 2012; Rezania et al., 2012; Guo et al., 2013b; Hua et al., 2013). Here, we show that the use of BMP inhibitors to specify pancreatic cells promotes the precocious induction of endocrine differentiation in PDX1+ pancreatic progenitors, which results in the formation of polyhormonal cells. Furthermore, we have identified simplified culture conditions that replicate fetal endocrine development and allow for the precise and efficient generation of PDX1+ and PDX1+/NKX6.1+ progenitor populations without precocious activation of the endocrine marker NEUROG3. Importantly, subsequent induction of endocrine differentiation in correctly specified PDX1+/NKX6.1+ progenitor cells results in the formation of glucose-responsive insulin-expressing beta-like cells in vitro within less than 3 weeks. Our study therefore details a simplified directed differentiation protocol that closely recapitulates key aspects of human endocrine development and results in the formation of large numbers of glucose-responsive beta-like cells under cell culture conditions.

### Results

**Pancreatic differentiation of hESCs using a large-scale culture system results in two distinct subsets of insulin-producing cells**

To generate pancreatic beta-like cells from human PSC, we established a scalable three-dimensional suspension culture system based on previously reported methods (Rezania et al., 2012; Schulz et al., 2012) (Fig 1A). To monitor the generation of live insulin-producing cells and facilitate their isolation, we employed the recently published INS$^{GFP/W}$ reporter cell line (Micallef et al., 2012) in which green fluorescence protein (GFP) expression is under the control of the endogenous insulin promoter. Using this differentiation protocol, GFP reporter expression was readily observed at day 13 and increased thereafter, resulting in an average of 37 ± 8% GFP+ cells between days 19 and 24 (Fig 1B–D). The validity of GFP as an accurate substitute for insulin was verified by staining with an insulin specific antibody, which revealed an even higher percentage of insulin-producing cells (up to 60%) likely due to delayed accumulation of the fluorescence marker (Fig 1E). Similar results were obtained with an antibody specific to human C-peptide, excluding antibody reactivity due to insulin uptake from culture media (Fig 1E).

Co-staining for human C-peptide and glucagon (GGC), a hormone normally produced by alpha cells, showed that 4.3% and 13.2% of all cells exhibited a polyhormonal phenotype at day 13 and day 19, respectively (Fig 1F). Co-staining for C-peptide and NKX6.1 at day 20 indicated the presence of some double-positive beta-like cells (Fig 1G). Quantitative flow cytometry analysis revealed that the proportion of insulin and NKX6.1 double-positive beta-like cells increased from less than 2.5% at day 13 to approximately 12% cells at day 19 of total cells (Fig 1G). Ultrastructural analysis of differentiated cultures showed cells containing secretory vesicles with an
electron-dense core surrounded by an electron-light halo (Fig 1H), a morphology reminiscent of insulin vesicles that are found in human beta cells. However, the majority of cells exhibited a mixture of secretory granules usually found in non-beta cells of human pancreas preparations (Fig 1H). Thus, differentiation experiments employing published protocols (Rezania et al, 2012; Schulz et al,
2012) result in the efficient generation of two distinct insulin-producing cell populations: INS+ cells that do not co-express the critical TF NKX6.1 and manifest as polyhormonal cells, and INS+/NKX6.1+ beta-like cells that more closely resemble human beta cells. Notably, INS+/NKX6.1+ beta-like cells are absent from cultures at earlier time points but appear and increase in number at later stages of differentiation, suggesting that they are derived from a distinct progenitor cell type.

**Defining the temporal activities of individual signaling factors to efficiently generate PDX1+ and PDX1+/NKX6.1+ pancreas progenitor populations while preventing precocious induction of endocrine differentiation**

To characterize the type of progenitors present in differentiating cultures at the point of endocrine induction, we performed a detailed time-course analysis for the expression of pancreatic markers PDX1, NKX6.1, NEUROG3, GCG, and INS (Supplementary Fig S1). High expression of the progenitor marker PDX1 was efficiently induced and maintained starting 1 day after the combined addition of retinoic acid (R), the SHH inhibitor cyclopamine (C), and the BMP inhibitor Noggin (N) to the culture media (referred to as RCN, day 6, Supplementary Fig S1A and B). Subsequent treatment with epidermal growth factor (EGF), KGF, and N (EKN) resulted in the robust generation of PDX1+/NKX6.1+ double-positive cells, reaching 67% of the total population at day 11 (Supplementary Fig S1A and B). Immunofluorescence analysis revealed that the RCN cocktail of factors widely used to generate pancreatic endoderm also induces precocious expression of NEUROG3 in PDX1+ pancreatic progenitors. Indeed, the expression of NEUROG3 can be detected as early as day 6, when NKX6.1 protein is absent from all cells (Supplementary Fig S1A and B). Consequentially, insulin-expressing cells that are first detected 4 days after NEUROG3 induction (starting at day 10) do not co-express NKX6.1 and are mostly polyhormonal (Fig 1F and G, and Supplementary Fig S1C). In contrast, INS/NKX6.1+ double-positive beta-like cells can be readily detected only at later time points (day 19, Fig 1G), suggesting that these cells differentiate from PDX1/NKX6.1 double-positive progenitor cells. We thus hypothesized that robust generation of PDX1+/NKX6.1+ progenitor cells prior to induction of NEUROG3 would allow efficient generation of beta-like cells in vitro. To determine which of the factors used between days 6 and 8 in the original protocol (R, C, and N) are responsible for the induction of PDX1, NKX6.1, and NEUROG3, we incubated spheres with each of the factors alone or in different combinations over days 6–8 (Fig 2A). Basal media with B27 but lacking any additional factors served as the control condition. At the end of day 8, each of these six conditions was further subdivided into three different treatment groups: Media composition remained the same as during days 6–8 (group 1) or changed either to EK (group 2) or to EKN (group 3), resulting in 18 individual experimental conditions (Fig 2A). Spheres cultured under each condition were analyzed at day 9.5 by flow cytometry to quantify the expression of PDX1 and NKX6.1, and by conventional immunofluorescence analysis for NKX6.1 and NEUROG3 expression. As shown in Fig 2B, spheres within group 1 that had been exposed to retinoic acid during days 6–8, either alone or in combination with other factors (conditions 4, 5, and 6), exhibited highly efficient generation of PDX1+ progenitors (> 88%), while the addition of C or N alone (conditions 2 and 3) did not result in enhanced generation of PDX1+ cells over basal media alone. NKX6.1 was induced only weakly in all group 1 conditions, with the exception of RC (condition 5), which produced 45% PDX1/NKX6.1 double-positive cells. NKX6.1 expression was also strongly induced when cells were exposed to retinoic acid alone or in combination with other factors followed by treatment with EK (group 2) or EKN (group 3) (Fig 2B and C, conditions 10–12 and 16–18). Endocrine differentiation, marked by NEUROG3 expression, was noted only when spheres had been exposed to N, either between days 5 and 9.5 (Fig 2C, conditions 3, 6, 9, and 12) or starting at the end of day 8 (Fig 2C, group 3, conditions 13–18). Very few NEUROG3+ cells were detected in all other conditions (Fig 2C, conditions 1, 2, 4, 5, 7, 8, 10, and 11). qPCR analysis at day 8 of NEUROG3 and its downstream target NKX2.2 mRNA transcripts revealed significantly lower levels of these endocrine markers with R treatment when compared to the commonly employed RCN condition (Supplementary Fig S1D). Notably, the addition of vitamin C, recently shown to reduce endocrine differentiation in hESCs (Rezania et al, 2014), did not significantly lower NEUROG3 or NKX2.2 transcripts in our suspension culture system during RCN or R treatment (Supplementary Fig S1D). Taken together, these results indicate that R followed by EK treatment leads to highly efficient generation of PDX1+/NKX6.1+ progenitors (90%) and that the formation of bona fide NEUROG3-positive endocrine precursors is induced by treatment with N (Fig 2A–C, condition 10, green gates). Thus, by defining the temporal activities of individual signaling factors alone and in combination, we can induce transcription factor expression patterns characteristic of different human embryonic pancreatic progenitor cells types (PDX1+ and PDX1+/NKX6.1+ progenitors) without precocious induction of endocrine differentiation.

**Recapitulating human pancreas organogenesis to generate endocrine progenitors**

This improved and simplified differentiation protocol provides the basis for subsequent efficient formation of insulin-producing cells in suspension (Fig 3A). Endocrine differentiation in PDX1/NKX6.1 double-positive cells was induced by exposure to a cocktail of factors consisting of TBP (T), ALK inhibitor (A), N, and K (TANK) which have previously been shown to activate NEUROG3 expression while maintaining high expression of PDX1 and NKX6.1 (Nostro et al, 2011; Rezania et al, 2012) (Fig 3A and B). Importantly, while NEUROG3 protein was undetectable before TANK treatment (Fig 3C, day 9), cells exhibiting nuclear accumulation of NEUROG3 protein appeared as early as 1 day following TANK treatment (Fig 3C, day 10). Thus, the expression of the pro-endocrine factor NEUROG3 is rapidly induced through TANK treatment once PDX1+/NKX6.1+ progenitors are specified (Fig 3B, day 9). In contrast to the near-uniform generation of PDX1+ and PDX1+/NKX6.1+ progenitor populations following appropriate stimulation, endocrine differentiation appears to be confined to a smaller population of cells. This observation can be explained by the very short half-life of the NEUROG3 protein (Roark et al, 2012), which allows only transient detection of this marker in cells undergoing endocrine differentiation. However, NEUROG3+ cells continued to be present when clusters were exposed to the endocrine differentiation cocktail for 5 days (Fig 3C, day 14), indicating that endocrine cells were being
generated throughout this period. To further characterize the progenitors present in our cultures at the initiation of endocrine differentiation, we analyzed the expression of NKX2.2, a downstream target of NEUROG3. NKX2.2 has recently been reported to have distinct expression patterns during pancreatic organogenesis in mouse and human (Jennings et al., 2013). While Nkx2.2 is readily detectable in mouse pancreatic progenitor cells before Neurog3 expression, NKX2.2 protein is only observed after endocrine commitment during human pancreas development. Similarly, we detected NKX2.2 protein expression only after endocrine commitment during human pancreas development. Similarly, we detected NKX2.2 protein expression only after endocrine commitment is initiated at day 10, but not before in either PDX1+ or PDX1+/NKX6.1+ progenitors (Fig 3C, data not shown). Of note, some NKX2.2+ cells at day 10 co-express NEUROG3, and increasing numbers of NKX2.2+/NEUROG3− cells are found at later time points (Fig 3C). These data suggest that NKX2.2 could serve as a lineage tracer for human cells that have undergone endocrine differentiation induced by transient NEUROG3 expression. In summary, we have established a novel differentiation strategy that faithfully recapitulates human pancreas organogenesis and allows for the precise control over the generation of PDX1+ and PDX1+/NKX6.1+ progenitors.

Efficient generation of PDX1+/NKX6.1+ pancreatic progenitor cells prior to endocrine induction results in glucose-responsive beta-like cells

To test the hypothesis that precocious activation of NEUROG3 expression results in immature polymorphic cells and not INS/NKX6.1 double-positive beta-like cells, we initiated endocrine differentiation at day 7 in PDX1+ pancreatic progenitors by exposing the cells to NEUROG3 inducers ALKi and Noggin (Supplementary Fig S2A). While some single-hormone-positive cells were present at day 13, many endocrine cells were double-positive for C-peptide and glucagon (Supplementary Fig S2B). In further support of our hypothesis, virtually all C-peptide-positive cells lacked expression of
NKX6.1 (Supplementary Fig S2C). To test whether correctly specified PDX1+/NKX6.1+ progenitor cells undergo differentiation toward INS/NKX6.1 double-positive beta-like cells, we transferred spheres differentiated using our new method into a basal media without additional growth factors and monitored the establishment of beta-like cells (Fig 4A). The percentage of GFP+ cells increased from day 13 to day 19, reaching an average of 23 ± 6% human C-peptide-positive cells at days 19–21, likely reflecting continuous generation of insulin-producing cells for ~4 days after removal of NEUROG3-inducing factors (Fig 4B and C). Immunofluorescence analysis of insulin-producing cells revealed co-expression and nuclear localization of TFs critical for beta cell function (PDX1,
NKX6.1, and NKX2.2), but very few polyhormonal cells (Fig 4D). Flow cytometry analysis of differentiated clusters showed a high percentage of total cells (black gates) and C-peptide-positive beta-like cells (green gates) co-staining for PDX1, NKX6.1, NKX2.2, ISL1, PAX6, NEUROD1, and chromogranin A (CHGA) (Fig 4E). These markers are normally found in both pancreatic progenitors and mature beta cells. Quantification of C-peptide+ beta-like cells co-staining for PDX1, NKX6.1, NKX2.2, ISL1, NEUROD1, PAX6, and CHGA showed 84% ± 7%, 75% ± 20%, 92% ± 5%, 86% ± 5%, 95% ± 4%, 93% ± 5%, and 93% ± 4% double-positive cells, respectively (Fig 4F). Notably, only 3.2% of all differentiated cells co-expressed C-peptide and the hormone glucagon (Fig 4E, red gate). An important hallmark of mature human beta cells is their restricted proliferative capacity. While 9.1 ± 3.7% of C-peptide-negative cells were actively proliferating, only 0.5 ± 0.6% of C-peptide+ beta-like cells co-stain for the proliferation marker Ki-67, indicating their terminal differentiation state (Supplementary Fig S3A and B). Thus, our optimized differentiation strategy results in the predominant generation of post-mitotic, insulin-producing beta-like cells that co-express critical beta cell markers.

To further characterize gene expression in beta-like cells at days 19–20, we took advantage of the GFP live marker to compare sorted GFP+ beta-like cells and GFP− populations to purified human islets. hESC-derived beta-like cells showed high levels of insulin gene transcripts, comparable to cadaveric islet preparations, while GFP-negative populations exhibit only insignificant levels of the hormone (Fig 5A). We also detected transcript levels for two other hormones (GCG and SST) in GFP+ cells, likely due to contamination by the small number of polyhormonal cells also expressing the GFP reporter (Figs 5A and 4D and E). Consistent with the immunofluorescence analysis (Fig 4D), transcripts for the TFs PDX1, NKX6.1, and NKX2.2 normally found in both progenitor and mature beta cells were expressed at comparable levels in GFP−, GFP+, and islet cells (Fig 5B). Transcripts for the mature human beta cell transcription factors MAFA and MAFB were robustly expressed in human islets and enriched in beta-like cells compared to GFP− populations. MAFB transcript levels in beta-like cells were similar to human islets; MAFA expression levels were slightly lower (Fig 5B). Other genes important for human beta cell functionality, including the KATP channel components potassium inwardly rectifying
channel, subfamily J, member 11 (KIR6.2, also known as KCNJ11) and ATP-binding cassette, subfamily C, member 8 (SUR1, also known as ABCC8), the glucose metabolism enzyme glucokinase (GCK, also known as HK4), and the prohormone convertase 1/3 (PC1/3) necessary for insulin biosynthesis, were enriched in GFP-positive beta-like cells at levels similar to or exceeding those found in human islets (Fig 5C). In contrast, mRNA levels for the progenitor marker SOX9 were reduced in beta-like cells compared to GFP/−/C0 progenitors (Fig 5D). The somewhat higher SOX9 expression in human islets is likely the result of contamination with SOX9-positive duct cells. Thus, our gene expression analysis suggested that hESC-derived beta-like cells possess the molecular machinery necessary for beta cell function, including insulin biosynthesis and glucose metabolism. Further investigations revealed that day 19 beta-like cells contain 2.5 ± 1.2 μg, 0.32 ± 0.12 μg, and 310 ± 143 ng insulin, human C-peptide, and proinsulin per μg DNA, respectively (Fig 5E). These values are comparable to ~2.8 μg insulin, ~0.55 μg C-peptide, and ~150 ng proinsulin per μg DNA for human islets as recently published (Rezania et al, 2014). Western blot analysis for proinsulin and mature insulin further confirmed efficient insulin protein processing in hESC-derived beta-like cells, reaching 59 ± 2% of the extent of processing observed in purified human islets (Supplementary Fig S4A and B). Ultrastructural analysis of differentiated cell clusters by transmission electron microscopy revealed that many cells contained secretory vesicles exhibiting electron-dense cores or rod-like structures, akin to what is observed in human beta cells (Fig 5F). To further investigate the functional properties of in vitro differentiated beta-like cells, we performed glucose-stimulated insulin secretion assays, in which we measured the release of human C-peptide, a by-product of endogenous insulin...
biosynthesis secreted in an equimolar ratio to insulin. hESC-derived beta-like cells analyzed at days 19–21 responded to an increase in glucose concentration from 2.8 mM to 16.7 mM by secreting 1.8 ± 0.9 fold more C-peptide, a response similar to the 1.9 ± 0.6-fold increase detected with human islets (Fig 5G). Thus, beta-like cells generated by our optimized differentiation strategy express critical beta cell genes, synthesize high levels of mature insulin, exhibit ultrastructural features of bona fide beta cells, and secrete endogenous insulin in response to changes in physiological concentrations of glucose.

**hESC-derived beta-like cells remain glucose responsive after short-term transplantation**

To determine whether hESC-derived beta-like cells can maintain their glucose responsiveness *in vivo*, we transplanted approximately 5 million cells under the kidney capsule of immunodeficient mice (days 19–21 spheres consisting of progenitors and beta-like cells). Mice transplanted with 4,000 human islets served as controls. Seven to 10 days post-surgery, human C-peptide levels were measured in overnight fasted mice, before and after the administration of a glucose bolus. As expected, mice that received human islet grafts exhibited low levels of insulin secretion upon fasting, followed by a marked increase in circulating insulin after glucose challenge (average of 221 ± 116 pm, Fig 6A). Similar to mice carrying human islets, fasted mice transplanted with hESC-derived beta-like cells had low levels of circulating C-peptide. Upon glucose administration, C-peptide concentrations in sera of these mice also increased, albeit at lower levels than in mice transplanted with human islets (average of 40 ± 28 pm, Fig 6A). This lower number might be explained in part by the different numbers of cells transplanted in the human islet and beta-like cell groups. Indeed, each human islet contains on average 1,000 cells, of which 50% are beta cells (Cabrera et al, 2006). Thus, 4,000 human islets contain approximately 2.0 × 10^6 bona fide beta cells. Since hESC-differentiated spheres contain on average 23% beta-like cells, only about 1.15 × 10^6 beta-like cells were transplanted per mouse. Normalization based on beta cell number indicates that hESC-derived beta-like cells secreted 70 ± 48 pm human C-peptide per 2.0 × 10^6 cells, representing approximately one-third of the insulin secreted from each human cadaveric beta cell (Fig 6A). Hematoxylin and eosin staining, together with immunofluorescence analysis of the hESC grafts at 2 weeks post-transplantation, demonstrated prominent islet-like structures positive for human C-peptide (Fig 6B and C). Beta-like cells also maintained co-expression of the key beta cell transcription factor PDX1+ pancreatic progenitors. Subsequent exposure to EGF and KGF results in the rapid and effective activation of NKX6.1 in these cells, generating PDX1+/NKX6.1+ progenitor cells with the ability to

Transplantation of a smaller number of human islets (1,500 islets) reduces blood glucose levels only for 7 days post-transplantation, after which hyperglycemia returned (Fiaschi-Taesch et al, 2010). Our surgical procedure permits the transplantation of ~1.15 × 10^5 beta-like cells, substantially less than the ~2.0 × 10^5 beta cells present in the 4,000 human islets previously found to be required for the long-term reversal of diabetes. Hence, the observed reduction in BG levels, but lack of complete diabetes reversal in mice bearing hESC-derived transplants, is not unexpected given this technical constraint. Taken together, our *in vivo* data demonstrate that hESC-derived beta-like cells maintain their differentiated phenotype and remain glucose responsive after a short engraftment period *in vivo* and highlight their potential therapeutic value.

**Discussion**

Herein, we describe a simplified differentiation protocol replicating key steps of embryonic pancreas organogenesis for the defined generation of human pancreatic progenitor and endocrine cell types from hESCs that results in the formation of glucose-responsive beta-like cells *in vitro*. hESC-derived beta-like cells exhibit key features of cadaveric human beta cells both *in vitro* and *in vivo*, most notably their ability to respond to physiological increases in glucose concentrations by secreting insulin. Gene expression analysis of beta-like cells indicates the presence of factors essential for beta cell function, proper biosynthesis of mature insulin, glucose metabolism, and insulin secretion at levels comparable to human islets. In addition, beta-like cells display ultrastructural features of bona fide human beta cells, such as appropriate secretory vesicles. Thus, critical elements necessary for the generation and appropriate processing, packaging, and storing of insulin in its bioactive mature form are present in these hESC-derived cells. Finally, beta-like cells remained functional after short-term transplantation and reduced blood glucose levels in a murine model of diabetes, further confirming the correct differentiation state of the cells.

Recently, two other groups have reported the derivation of glucose-responsive beta-like cells from hESCs that share many characteristics of the beta-like cells described here (Pagliuca et al, 2014; Rezania et al, 2014). However, both studies focused on optimizing the later stages of direct differentiation, while employing parts of published protocols, namely the addition of RCN, to establish pancreatic progenitor populations. Our data demonstrate that the generation of pancreatic progenitors using this method also results in the undesirable generation of immature polyhormonal endocrine cells that lack expression of the critical beta cell transcription factor NKX6.1. Indeed, both published studies do note appreciable populations of C-peptide/insulin-positive cells that lack NKX6.1 expression. We demonstrate that polyhormonal cells result from precocious endocrine induction in PDX1+ pancreatic progenitors (lacking NKX6.1 expression), which can be avoided by omitting BMP inhibitors during the pancreas specification stage. Further, our detailed analysis of the effects of individual RCN factors on the expression of key pancreatic markers revealed that retinoic acid alone is sufficient to induce proficient generation of more than 98% PDX1+ pancreatic progenitors. Subsequent exposure to EGF and KGF results in the rapid and effective activation of NKX6.1 in these cells, generating PDX1+/NKX6.1+ progenitor cells with the ability to
give rise to beta-like cells in vitro. These simplified differentiation conditions enable the efficient generation of human pancreatic and more restricted endocrine progenitor populations from pluripotent stem cells without unwanted formation of polyhormonal cells. Thus, we conclude that this simplified differentiation protocol more closely resembles key aspects of early human pancreas development and, as such, represents an improvement over published protocols.

Although the mechanisms of endocrine differentiation in vitro are not completely understood, previous studies in rodents have shown an important role for Notch signaling. While initially required for the generation of competent progenitor cells, a subsequent reduction of Notch signaling is necessary for the induction of Neurog3 expression that initiates endocrine differentiation (Shih et al., 2012). In the context of in vitro differentiation, previous studies have shown that direct inhibition of Notch signaling by gamma secretase inhibitors or the use of BMP and TGFβ/ALK inhibitors results in increased insulin expression at later stages (Mfopou et al., 2010; Nostro et al., 2011; Pagliuca et al., 2014; Rezania et al., 2014). We employed BMP and ALK inhibition over a 5-day window to induce NEUROG3 expression specifically in PDX1+/NKX6.1+ progenitors, which resulted in the efficient generation of INS+/NKX6.1+ beta-like cells, while only few polyhormonal cells were observed (~3%). Likely these unwanted cells originate from the small percentage of PDX1 pancreatic progenitors present at the time of endocrine induction. In contrast to the formation of PDX1+/NKX6.1+ progenitors that occurs rapidly (36–48 h after the addition of inducing factor(s) and uniformly in the majority of cells, endocrine differentiation occurs over a prolonged period and is confined to a small
subset of total cells. This might be a reflection of the situation observed during normal human pancreas development where only few progenitor cells initiate the endocrine differentiation program at any given time (Jennings et al., 2013). While simultaneous widespread induction of endocrine differentiation in a majority of PDX1+/NKX6.1+ progenitor population would greatly reduce differentiation time and increase beta-like cell yield, our results point to a regulation of NEUROG3 expression that requires subtle, yet temporally precise adjustment that appears more complex than just notch inhibition. As our differentiation protocol allows for a tight control of NEUROG3 expression, it could be used in future studies to identify novel regulators of NEUROG3 gene expression, and ideally to achieve uniform NEUROG3 activation during direct differentiation in vitro.

While cadaveric islet preparations are widely accepted as the gold standard for studying human beta cells, several problems associated with their use remain. For example, their performance and utility depend on a number of confounding factors: genetic variance, age and life style of the donor, isolation time, islet purity, and shipping conditions. By eliminating the constraints of availability and reproducibility, we anticipate that hESC-derived beta-like cells will provide an important tool in accelerating a more complete understanding of the biology of human beta cells.

Taken together, our fast and simplified protocol provides precise temporal control over the generation of subsequent pancreatic progenitor and endocrine cell types and results in the establishment of human beta-like cells that exhibit glucose responsiveness in vitro and in vivo. Our suspension-based direct differentiation approach is scalable, and our ability to produce large numbers of beta-like cells will further accelerate efforts in delivering a safe and efficient cell therapy to patients suffering from diabetes. Furthermore, through the production and maintenance of different developmental cell populations, our approach can be used for more detailed investigations into human pancreas development and human beta cell function that were previously impossible due to limited donor material, such as large-scale drug screens and genomewide gene function studies.

Material and Methods

Cell culture

Undifferentiated MEL1 INSGFP/W reporter cells (Micallef et al., 2012) were maintained on mouse embryo fibroblast feeder layers (Millipore) in hESC media as described (Guo et al., 2013b). Suspension-based differentiations were carried out as follows. Briefly, confluent cultures were dissociated into single-cell suspension by incubation with TrypLE (Gibco). Cells were counted and each well of 6-well cultures were dissociated into single-cell suspension by incubation with Accumax (innovative cell technologies). For sorting, cell suspension were filtered and re-suspended in d1 media [RPMI (Gibco) containing 0.2% FBS, 1:2,000 ITS (Gibco), 100 ng/ml activin A, and 50 ng/ml WNT3a (R&D Systems)]. Clusters from three wells were combined into two wells at this point and distributed into fresh low attachment plates in 5.5 ml d1 media. Media thereafter were changed daily, by removing either 4.5 ml media (at the end of d1) or 5.5 ml media the following days and adding back 5.5 ml fresh media until day 9. After day 9, only 5 ml of media was removed and added daily. Differentiation employing published protocols has been described (Rezania et al., 2012; Schulz et al., 2012). Media in our simplified differentiation protocol consist of the following: d2: RPMI containing 0.2% FBS, 1:2,000 ITS, and 100 ng/ml activin A; d3: RPMI containing 0.2% FBS, 1:1,000 ITS, 2.5 μM TGFβI (CalBioChem), and 25 ng/ml KGF (R&D Systems); d4-5: RPMI containing 0.4% FBS, 1:1,000 ITS, and 25 ng/ml KGF; d6-7: DMEM (Gibco) with 25 mM glucose containing 1:100 B27 (Gibco), 3 nM TTNBP (Sigma); d8: DMEM with 25 mM glucose containing 1:100 B27, 3 nM TTNBP, and 50 ng/ml EGF (R&D Systems); d9: DMEM with 25 mM glucose containing 1:100 B27, 50 ng/ml EGF, and 50 ng/ml KGF; d10-14: DMEM with 25 mM glucose containing 1:100 B27, 500 nM LDN-193189 (Sgentem), 30 nM TBP (Millipore), 1,000 nM ALK1 II (Axxora), and 25 ng/ml KGF; and d15-21: DMEM with 2.8 mM glucose containing 1:100 Glutamax (Gibco) and 1:100 NEAA (Gibco). Human islets were from Prodo Laboratories or the UCSF Islets and Cellular Production Facility.

Mice

NOD.Cg-Prkdscid il2rgtm1Wjl/SzJ mice (NSG) were obtained from Jackson Laboratories. Mice used in this study were maintained according to protocols approved by the University of California, San Francisco Committee on Laboratory Animal Resource Center. For kidney capsule grafts, approximately 5.0 × 106 hESC-differentiated cells in spheres and 4,000 human islet equivalents were transplanted as described (Szot et al., 2007; Russ & Efrat, 2011). For glucose-induced insulin secretion, mice were fasted overnight and serum was collected before and after intraperitoneal administration of 3 g/kg D-glucose solution. For induction of diabetes, mice were administered 35 mg/kg streptozotocin via intraperitoneal injection for 5 days. Graft-bearing kidneys were removed for immunofluorescence analysis. No statistical method was employed to determine sample size, mice were not randomized, and analysis was not blinded.

Cell sorting and flow cytometric analysis

Briefly, spheres were collected and allowed to settle by gravity. Clusters were washed once in PBS and dissociated by gentle pipetting after 12- to 15-min incubation in Accumax (innovative cell technologies). For sorting, cell suspension were filtered and re-suspended in FACS buffer consisting of PBS (UCSF cell culture facility) containing 2 mM EDTA (Ambion) and 1% BSA (Sigma). Dead cells were excluded by DAPI (Sigma) staining. Cell sorting was performed on a FACSAria II (BD Bioscience). For flow-based analysis, dissociated cells were fixed with 4% paraformaldehyde (Electron Microscopy Science) for 15 min at room temperature, followed by two washes in PBS. Samples were either stored at 4°C or immediately stained with directly conjugated antibodies. Data analysis was performed with FlowJo software. Mouse glucagon and mouse human C-peptide antibodies were conjugated in-house by the UCSF Antibody Core and/or with Antibody Labeling Kits (Molecular Probes) according to manufacturer’s instructions. Commercially available directly conjugated antibodies are listed below:
Primary antibodies were employed as follows: Vectashield. Nuclei were visualized with DAPI. Images were

tions. Slides were washed in PBS-T and PBS before mounting in

Appropriate Alexa-conjugated secondary antibodies were

incubated overnight at 4°C. Spheres were fixed by adding 37°C warm 0.1 M sodium cacodylate solution (Sigma) containing 2% paraformaldehyde (Electron Microscopy Science) and 2.5% glutaraldehyde (Electron Microscopy Science), 3 μM CaCl₂ (Sigma), final pH 7.4. Spheres were then transferred to 4°C for approximately 18 h, followed by standard processing and analysis by the Electron Microscope Lab/Diabetes Center Microscope Core.

Electron microscopic analysis

Spheres were fixed by adding 37°C warm 0.1 M sodium cacodylate solution (Sigma) containing 2% paraformaldehyde (Electron Microscopy Science) and 2.5% glutaraldehyde (Electron Microscopy Science), 3 μM CaCl₂ (Sigma), final pH 7.4. Spheres were then transferred to 4°C for approximately 18 h, followed by standard processing and analysis by the Electron Microscope Lab/Diabetes Center Microscope Core.

Immunofluorescence analysis

Spheres were fixed by adding 37°C warm 0.1 M sodium cacodylate solution (Sigma) containing 2% paraformaldehyde (Electron Microscopy Science) and 2.5% glutaraldehyde (Electron Microscopy Science), 3 μM CaCl₂ (Sigma), final pH 7.4. Spheres were then transferred to 4°C for approximately 18 h, followed by standard processing and analysis by the Electron Microscope Lab/Diabetes Center Microscope Core.

qPCR analysis

Total RNA was isolated with TRizol (Sigma) or micro/mini RNeasy kit (Qiagen) and reverse-transcribed using the iScript cDNA Kit (Bio-Rad) according to manufacturer’s instructions. qPCR analysis was performed on an ABI 7900 HT Fast Real-Time PCR System (Applied Biosystems) and CFX Connect Real-Time System (Bio-Rad) using standard protocols. Primers were TaqMan probes (Applied Biosystems) and/or as published previously (Liu et al., 2014). P-values were calculated using a two-tailed Student’s t-test.

Content analysis

Insulin, human C-peptide, and proinsulin analyses were performed by measuring an aliquot of acidic ethanol lysed clusters with commercially available ELISA kits (insulin cat. 80-INSMR-CH10, human C-peptide cat. 80-CPTHU-CH01, and proinsulin cat. 80-PINHUT-CH01; all from Alpco). Total DNA was quantified by PicoGreen (Invitrogen) assay and normalized to the percentage of C-peptide-positive cells in each sample.

Western blotting for proinsulin/insulin

Cell lysates were resolved on 4–12% acrylamide gradient SDS–PAGE gels (NuPAGE, Invitrogen) normalized to cellular DNA (Quant-iT dsDNA, Molecular Probes). The samples were then electrophoresed into nitrocellulose membranes and immunoblotted with guinea pig anti-insulin, which recognizes both proinsulin and insulin, as previously described (Haataja et al., 2013). Immunoblotting with anti-tubulin was used as a confirmatory loading control. HRP-conjugated secondary antibodies (Jackson ImmunoResearch) were used for enhanced chemiluminescence detection (Millipore). The analysis was performed four times with isolated human islets used as a positive control.

Glucose-stimulated insulin secretion

Human islets or hESC-derived spheres were transferred into tubes and washed twice with Krebs–Ringer Bicarbonate buffer (KRB) containing 2.8 mM glucose. Samples were incubated for one hour in 2.8 mM glucose containing KRB to allow equilibration of cells. 2.8 mM buffer was removed and replaced with fresh KRB containing 2.8 mM glucose for one hour followed by incubation for another hour in KRB containing 16.7 mM glucose. After the incubation period, buffers were collected for human C-peptide-specific ELISA analysis using a commercially available kit (Alpco).

Supplementary information for this article is available online: http://emboj.embopress.org

### Table: Antibody and Manufacturer

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human PAX6-Alexa647</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>Islet-1-PE</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>NKX6.1-Alexa647</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>NKX6.1-PE</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>Chromogranin A-PE</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>NeuroD1-Alexa647</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>PDX1-PE</td>
<td>BD Bioscience</td>
</tr>
<tr>
<td>Ki-67-Alexa647</td>
<td>BD Bioscience</td>
</tr>
</tbody>
</table>

### Table: Antigen, Species, Dilution, and Manufacturer

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Species</th>
<th>Dilution</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human C-peptide</td>
<td>Mouse</td>
<td>1:200</td>
<td>Chemicon</td>
</tr>
<tr>
<td>Human C-peptide</td>
<td>Rat</td>
<td>1:1000</td>
<td>DSHB</td>
</tr>
<tr>
<td>Insulin</td>
<td>Mouse</td>
<td>1:1000</td>
<td>Sigma</td>
</tr>
<tr>
<td>Insulin</td>
<td>Guinea pig</td>
<td>1:500</td>
<td>DAKO</td>
</tr>
<tr>
<td>Glucagon</td>
<td>Mouse</td>
<td>1:1000</td>
<td>Sigma</td>
</tr>
<tr>
<td>NKX6.1</td>
<td>Mouse</td>
<td>1:100</td>
<td>DSHB</td>
</tr>
</tbody>
</table>
Acknowledgements
We thank members of the Hebrok laboratory and UCSF Diabetes Center for helpful comments and discussion. HAR was supported by a Richard G. Klein Fellowship and JDRF Fellowship (3-2012-266); TGH was supported by NIDDK training grant #T32DK007418. We also acknowledge flow cytometry and imaging facilities provided by the intramural Imaging and Flow Cytometry Core. Image acquisition was supported by the University of California, San Francisco Diabetes and Endocrinology Research Center (DERC) and UCSF Flow Cytometry Core. Image acquisition was performed at the Laboratory of PA was supported by NIH R01 DK48280. Work in the lab of VC was supported by the Life Sciences Discovery Fund grant #453677 and JDRF grant #17-2011-620. Stem cell research in the laboratory of MH is supported by a grant from the Leona M. and Harry B. Helmsley Charitable Trust (2012PG-T1D017). MH and PA acknowledge assistance from the Brehm Coalition for Discovery in Diabetes.

Author contributions
HAR, AVP, and MH designed, analyzed, and interpreted results. SP, VC, RB, GLS, and PA interpreted results. HAR, AVP, JIR, MG, TGH, LH, GLS, and TG performed experiments. HAR, AVP, TGH, and MH wrote the manuscript. HAR, AVP, JIR, TGH, GGN, and MH contributed to manuscript revision. All authors reviewed, edited, and approved the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

References